世界中の市場調査レポートを販売!当社に無いレポートもお探しします。

レポートナンバー 0000028695

皮膚科薬市場レポート2021−2031

Visiongain

Dermatological Drugs Market Report 2021-2031

発刊日 2021/01/14

言語英語

体裁PDF/588ページ

「PDF」版588ページ

0000028695

皮膚科薬市場レポート2021−2031
Dermatological Drugs Market Report 2021-2031

3,999 GBP

※ご請求は、お申込日のTTSレートで円換算し、消費税を加えた金額になります。
※販売価格はシングルユーザーライセンスのものとなります。
※シングルユーザーライセンスのレポートは印刷不可、およびライセンス期間は1年となります。
※印刷可能のレポートをご希望の場合は、デパートメントライセンス(ライセンス期間1年、ユーザー数5人)をご検討ください。
※詳しくはお問い合わせください。

無料サンプル

  • サンプルはお問い合わせください。

レポート概要

疾患別予測:(乾癬、皮膚炎、ニキビ、皮膚感染、その他の疾患)、皮膚感染薬別(Bepanthen/Bepanthol、 Protopic、Dermovate)、乾癬薬別(Humira、Stelara、Enbrel、Remicade。Taltz、Otezla)、皮膚炎薬別(Cubicin、Zyvox、Valtrex、Canesten、Lamisil、その他の皮膚炎薬)、投与経路別(外用、経口、非経口投与)、地域別、主要国市場別分析、プラス、主要皮膚科薬メーカーの分析、COVID-19回復シナリオ

このレポートは特に慢性尋常性乾癬と転移性悪性黒色腫(メラノーマ)に焦点を当て、既存および新規皮膚疾患治療薬について深く掘り下げます。Visiongainは低分子やバイオシミラーを含む、乾癬の治療に使用されている現在および今後出現する生物製剤について考察します。さらに、その他の皮膚疾患の新規治療薬における最近の進歩について要約し、皮膚科学における橋渡し研究と 層別化医療の概要を示します。患者と治療薬とのより適切なマッチングは、臨床医療と新薬や診断薬の開発の両面で大きな効果が期待されます。

COVID-19が医薬品のサプライチェーンに与える影響

国や企業がCOVID-19によってかつてない課題に直面する中で、COVID-19パンデミックが世界の医薬品産業のサプライチェーンに影響を及ぼし混乱が生じています。中国がAPIの製造および輸出量で世界をリードしているという事実によって懸念が一層強まりました。グローバルな製薬企業の多くは、2020年1月から3月までロックダウンを経験した中国から原料のバルクを輸入しています。

580ページのレポートに387の表と375の図、グラフを掲載しています。成長を続ける皮膚科薬市場には多くのビジネスチャンスが存在しています。

レポート詳細

目次

1. Report Overview
1.1 Introduction to Dermatological Drugs Market
1.2 What are the Objectives of this Report?
1.3 Reasons For Doing The Study
1.4 What is the Scope of the Report?
1.5 Dermatological Drugs Market Definition
1.6 Why You Should Read This Report
1.7 What This Report Delivers
1.8 Key Questions Answered By This Analytical Report Include:
1.9 Who is This Report For?
1.10 Methodology
1.10.1 Primary Research
1.10.2 Secondary Research
1.10.3 Market Evaluation & Forecasting Methodology
1.11 Frequently Asked Questions (FAQs)
1.12 Associated Visiongain Reports
1.13 About Visiongain

2 Executive Summary
2.1 Key Highlights

3 Dermatology Industry Overview
3.1 Overview
3.1.1 Two Defence Strategies For Drug Development
3.1.2 Humoral Immunity
3.1.3 Cellular Immunity
3.1.4 Markers Of Self
3.1.5 Humoral Immunity: B Lymphocytes
3.1.6 Cellular Immunity: T Lymphocytes
3.1.7 Regulatory T Cells
3.1.8 Cytotoxic T Cells
3.1.9 Natural Immunity

4 Market Dynamics
4.1 Market Drivers
4.1.1 Why there is Increased Demand from Emerging Markets
4.1.2 Awareness and Advance Healthcare Systems
4.1.3 Cost-Effectiveness And Increasing Investments
4.1.4 Impact of Skin Disease on Quality of Life
4.1.5 Improving Quality of Care through Innovation
4.2 Restraints in the Global Market
4.2.1 How High Prices Are Restraining Growth of the Market
4.2.2 How Gaps in Knowledge Hampering the Growth?
4.2.3 Research Efforts And Funding Do Not Match With The Relative Disability Of Skin Diseases
4.3 Opportunities in the Global Market
4.3.1 Affordable Care Act: Expanding Medicare Coverage
4.3.2 Recent Recognition Of Skin Disease At The Global Stage
4.3.3 Skin Conditions Contributed 1.79% To The Total Global Burden Of Disease
4.4 Challenges in the Global Market
4.4.1 Impact of COVID-19 on Pharma Supply Chains
4.4.2 Disruption of Clinical Trials Due to Pandemic Breakout
4.4.3 Understanding The Impact Of Dermatological Diseases In Resource-Poor Areas Is Challenging
4.5 SWOT Analysis
4.5.1 Strengths of Dermatology Drugs Market
4.5.1.1 Ageing Population Driving Need for Dermatology Drugs
4.5.1.2 Demand from Emerging Markets Continue
4.5.1.3 Promising R&D Pipeline in the Dermatology Drugs Market
4.5.1.4 Increasing Awareness about Dermatology Drugs and Treatments
4.5.2 Weaknesses of Dermatology Drugs Market
4.5.2.1 High Costs Associated with Blood Plasma Therapy
4.5.2.2 Barriers to Dermatology Drugs Market Entry
4.5.3 Opportunities in the Global Dermatology Drugs
4.5.3.1 Constant Improvements in Dermatology Drugs & Treatment
4.5.3.2 The Method Of Treatment For Skin Problems Will Be Subject To Innovation Too
4.5.4 Threats in the Global Market
4.5.4.1 Approval Process For New Dermatology Drugs Is Overseen By Various Regulatory Bodies
4.5.4.2 Productivity Gap in the Dermatology Treatment Market
4.6 Porter’s Five Forces Analysis
4.6.1 Overview
4.6.2 Threat of New Entrants - Low
4.6.3 Bargaining Power of Suppliers - Low
4.6.4 Bargaining Power of Buyers - Moderate
4.6.5 Threat of Substitutes - Moderate to Low
4.6.6 Competitive Rivalry - High

5 Global Dermatological Drugs Market
5.1 Global Market Outlook
5.1.1 Growing Demand For Efficient Treatment
5.1.2 Growth In The Number Of Investment
5.1.3 The Size Of The Patient Population Determines Market Size of Dermatology Market
5.1.4 Pre-COVID Market Scenario
5.1.5 COVID-19 Impact Recovery Scenarios (V, U, W, L)
5.2 Regional Dermatological Drugs Market Forecast 2021-2031
5.2.1 Asia Pacific market and the rest of the world will most likely emerge in the coming years as highly promising markets
5.2.2 Regional Market Share Analysis
5.2.3 Pre-COVID Market Scenario
5.2.4 COVID-19 Impact Recovery Scenario (V, W, U, L)
5.3 Disease Segment Market Forecast 2021-2031
5.3.1 Increased Incidence Of Skin Cancer And Other Skin Disorders Are The Factors Contributing To The Market Growth Of Dermatology Drugs
5.3.2 Disease Segment Market Share Analysis
5.3.3 Pre-COVID Market Scenario
5.3.4 COVID-19 Impact Recovery Scenario (V, W, U, L)
5.4 Skin Infection Drugs Segment Market Forecast 2021-2031
5.4.1 Skin Infection Drugs Segment Outlook
5.4.1.1 Bacterial Infections
5.4.1.2 Impetigo/Ecthyma
5.4.1.3 Cellulitis
5.4.1.4 Treatments Available
5.4.1.5 Necrotizing Subcutaneous Infection
5.4.1.6 Treatments Available
5.4.1.7 Fungal Infections
5.4.1.8 Candidiasis
5.4.1.9 Treatments Available
5.4.1.10 Tinea Versicolor
5.4.1.11 Treatments Available
5.4.1.12 Viral Infections
5.4.1.13 Herpes Simplex
5.4.1.14 Treatments Available
5.4.1.15 Herpes Zoster
5.4.1.16 Treatments Available
5.4.1.17 Warts
5.4.1.18 Treatments Available
5.4.2 Skin Infection Treatment Pipeline
5.4.2.1 Anti-Infective Market
5.4.3 Skin Infection Drugs Segment Market Share Analysis
5.4.4 Pre-COVID Market Scenario
5.4.5 COVID-19 Impact Recovery Scenario (V, W, U, L)
5.5 Psoriasis Drugs Segment Market Forecast 2021-2031
5.5.1 Psoriasis Drugs Segment Outlook
5.5.1.1 Subtypes
5.5.1.2 Plaque Psoriasis
5.5.1.3 Guttate Psoriasis
5.5.1.4 Erythrodermic Psoriasis
5.5.1.5 Pustular Psoriasis
5.5.1.6 Psoriasis of the Nails
5.5.1.7 Treatments Available
5.5.1.8 Topical Therapies Available
5.5.1.9 Emollients
5.5.1.10 Keratolytics
5.5.1.11 Topical Corticosteroids
5.5.1.12 Vitamin D3 Products
5.5.1.13 Tazarotene
5.5.1.14 Tar Preparations
5.5.1.15 Anthralin
5.5.1.16 Topical Immunomodulators
5.5.1.17 Intralesional Therapy
5.5.1.18 Phototherapy with UVB
5.5.1.19 Photochemotherapy (PUVA)
5.5.1.20 Systemic Therapy
5.5.1.21 Methotrexate
5.5.1.22 Acitretin
5.5.1.23 Cyclosporine
5.5.1.24 Hydroxyurea
5.5.1.25 Cytokine Antagonists and Other Immunomodulators
5.5.2 Psoriasis Treatment Benefits And Risks
5.5.2.1 Major Engineered Protein Treatments In Use
5.5.2.2 Etanercept (Enbrel)
5.5.2.3 Adalimumab (Humira)
5.5.2.4 Infliximab (REMICADE)
5.5.2.5 Ustekinumab (STELARA)
5.5.2.6 Alefacept (Amevive)
5.5.2.7 Cost of Treatment
5.5.2.8 Psoriasis Treatment Pipeline
5.5.2.9 Psoriasis Treatment Market
5.5.3 Psoriasis Drugs Segment Market Share Analysis
5.5.4 Pre-COVID Market Scenario
5.5.5 COVID-19 Impact Recovery Scenario (V, W, U, L)
5.6 Dermatitis Drugs Segment Market Forecast 2021-2031
5.6.1 Dermatitis Drugs Segment Outlook
5.6.1.1 Irritant Contact Dermatitis
5.6.1.2 Available Treatments
5.6.1.3 Allergic response after re-exposure.
5.6.1.4 Available Treatments
5.6.1.5 Dermatitis Pipeline
5.6.2 Dermatitis Drugs Segment Market Share Analysis
5.6.3 Pre-COVID Market Scenario
5.6.4 COVID-19 Impact Recovery Scenario (V, W, U, L)
5.7 Acne Drugs Segment Market Forecast 2021-2031
5.7.1 Acne Drugs Segment Outlook
5.7.1.1 Comedonal
5.7.1.2 Papulopustular
5.7.1.3 Nodulocystic
5.7.1.4 Treatments Available
5.7.1.5 Retinoids
5.7.1.6 Antibiotics
5.7.1.7 Anti-inflammatory Drugs
5.7.1.8 Hormonal Therapy
5.7.1.9 Treatment Failure
5.7.1.10 Acne Treatment Pipeline
5.7.1.11 Acne Treatment Market
5.7.2 Acne Drugs Segment Market Share Analysis
5.7.3 Pre-COVID Market Scenario
5.7.4 COVID-19 Impact Recovery Scenario (V, W, U, L)
5.8 Route of Administration Segment Market Forecast 2021-2031
5.8.1 Route of Administration Segment Outlook
5.8.2 Route of Administration Segment Market Share Analysis
5.8.3 Pre-COVID Market Scenario
5.8.4 COVID-19 Impact Recovery Scenario (V, W, L, U)

6 North America Dermatological Drugs Market
6.1 North America Market Outlook
6.1.1 North America holds the biggest market share in dermatology drugs
6.2 North America Market Estimation & Forecast, 2021-2031
6.2.1 Pre-COVID Market Scenario
6.2.2 COVID-19 Impact Recovery Scenario (V, W, U, L)
6.3 Country Segment Market Forecast, 2021-2031
6.3.1 Country Market Share Analysis
6.3.2 Pre-COVID Market Scenario
6.3.3 COVID-19 Impact Recovery Scenario (V, W, U, L)
6.4 Disease Segment Market Forecast, 2021-2031
6.4.1 Pre-COVID Market Scenario
6.4.2 COVID-19 Impact Recovery Scenario (V, W, U, L)
6.5 Skin Infection Drugs Segment Market Forecast, 2021-2031
6.5.1 Pre-COVID Marker Scenario
6.5.2 COVID-19 Impact Recovery Scenario (V, W, U, L)
6.6 Psoriasis Drugs Segment Market Forecast, 2021-2031
6.6.1 Pre-COVID Market Scenario
6.6.2 COVID-19 Impact Recovery Scenario (V, W, U, L)
6.7 Dermatitis Drugs Segment Market Forecast, 2021-2031
6.7.1 Pre-COVID Market Scenario
6.7.2 COVID-19 Impact Recovery Scenario (V, W, U, L)
6.8 Acne Drugs Segment Market Forecast, 2021-2031
6.8.1 Pre-COVID Market Scenario
6.8.2 COVID-19 Impact Recovery Scenario (V, U, W, L)
6.9 Route of Administration Segment Market Forecast, 2021-2031
6.9.1 Pre-COVID Market Scenario
6.9.2 COVID-19 Impact Recovery Scenario (V, W, U, L)
6.10 US Dermatological Drugs Market
6.10.1 U.S. market represents 26% of the world market by value
6.10.2 Investigative Dermatology and The American Academy of Dermatology Association
6.10.3 Pre-COVID Market Scenario
6.10.4 COVID-19 Impact Recovery Scenario (V, U, W, L)
6.11 Canada Dermatological Drugs Market
6.11.1 Pharmaceutical Companies Are Re-Organizing And Adopting Strategies To Reduce Risk, And Overcome External Factors
6.11.2 Medical Education Materials Are Being Developed To Facilitate Uptake
6.11.3 Pre-COVID Market Scenario
6.11.4 COVID-19 Impact Recovery Scenario (V, W, U, L)

7 Europe Dermatological Drugs Market
7.1 Europe Market Outlook
7.1.1 Due To Its Easy Availability Of Dermatological Drugs, Europe Accounted For A Significant Market Share
7.2 Europe Dermatological Drugs Market Estimation & Forecast, 2021-2031
7.2.1 Pre-COVID Market Scenario
7.2.2 COVID-19 Impact Recovery Scenario (V, W, U, L)
7.3 Country Segment Market Forecast, 2021-2031
7.3.1 Country Market Share Analysis
7.3.2 Pre-COVID Market Scenario
7.3.3 COVID-19 Impact Recovery Scenario (V, W, U, L)
7.4 Disease Segment Market Forecast, 2021-2031
7.4.1 Pre-COVID Market Scenario
7.4.2 COVID-19 Impact Recovery Scenario (V, W, U, L)
7.5 Skin Infection Drugs Segment Market Forecast, 2021-2031
7.5.1 Pre-COVID Market Scenario
7.5.2 COVID-19 Impact Recovery Scenario (V, W, U, L)
7.6 Psoriasis Drugs Segment Market Forecast, 2021-2031
7.6.1 Pre-COVID Market Scenario
7.6.2 COVID-19 Impact Recovery Scenario (V, W, U, L)
7.7 Dermatitis Drugs Segment Market Forecast, 2021-2031
7.7.1 Pre-COVID Market Scenario
7.7.2 COVID-19 Impact Recovery Scenario (V, W, U, L)
7.8 Acne Drugs Segment Market Forecast, 2021-2031
7.8.1 Pre-COVID Market Scenario
7.8.2 COVID-19 Impact Recovery Scenario (V, W, U, L)
7.9 Route of Administration Segment Market Forecast, 2021-2031
7.9.1 Pre-COVID Market Scenario
7.9.2 COVID-19 Impact Recovery Scenario (V, W, U, L)
7.10 Germany Dermatological Drugs Market
7.10.1 Germany is the third-largest market for pharmaceuticals in an international comparison
7.10.2 The prices of widely used drugs in Germany are higher than elsewhere in the EU or in the U.S.
7.10.3 Pre-COVID Market Scenario
7.10.4 COVID-19 Impact Recovery Scenario (V, W, U, L)
7.11 UK Dermatological Drugs Market
7.11.1 The four countries of the United Kingdom have separate but cooperating public healthcare systems
7.11.2 Medical Insurance in driving the market
7.11.3 Due to Price Control the drugs are affordable in the UK
7.11.4 Pre-COVID Market Scenario
7.11.5 COVID-19 Impact Recovery Scenario (V, W, U, L)
7.12 France Dermatological Drugs Market
7.12.1 France provides the “best overall healthcare” in the world
7.12.2 The second-largest national market in the EU after Germany
7.12.3 Pre-COVID Market Scenario
7.12.4 COVID-19 Impact Recovery Scenario (V, W, U, L)
7.13 Italy Dermatological Drugs Market
7.13.1 Italy has one of the highest ratios of doctors per capita at 3.9 doctors per 1,000 patients
7.13.2 Servizio Sanitario Nazionale (Italian National Health Service, or SSN)
7.13.3 The Italian pharmaceutical market ranks among the top four in Europe
7.13.4 The Italian population is aging; the percentage over 65 years has already exceeded 20% and is set to rise still further
7.13.5 Pre-COVID Market Scenario
7.13.6 COVID-19 Impact Recovery Scenario (V, W, U, L)
7.14 Spain Dermatological Drugs Market
7.14.1 Spanish Agency of Medications and Healthcare Products
7.14.2 The Spanish pharmaceutical market is the fifth largest in the EU and ranks seventh in the world
7.14.3 A new reference price system has been implemented in Spain
7.14.4 Pre-COVID Market Scenario
7.14.5 COVID-19 Impact Recovery Scenario (V, W, U, L)
7.15 Rest of Europe Dermatological Drugs Market
7.15.1 Dermatology products account for less than 10% of the market
7.15.2 Pre-COVID Market Scenario
7.15.3 COVID-19 Impact Recovery Scenario (V, W, U, L)

8 Asia-Pacific Dermatological Drugs Market
8.1 Asia-Pacific has been third in terms of the dermatology drug market's value-added position
8.2 Asia-Pacific Dermatological drugs Market Estimation & Forecast, 2021-2031
8.2.1 Pre-COVID Market Scenario
8.2.2 COVID-19 Impact Recovery Scenario (V, W, U, L)
8.3 Country Segment Market Forecast, 2021-2031
8.3.1 Country Market Share Analysis
8.3.2 Pre-COVID Market Scenario
8.4 Disease Segment Market Forecast, 2021-2031
8.4.1 Pre-COVID Market Scenario
8.4.2 COVID-19 Impact Recovery Scenario (V, W, U, L)
8.5 Skin Infection Drugs Segment Market Forecast, 2021-2031
8.5.1 Pre-COVID Market Scenario
8.5.2 COVID-19 Impact Recovery Scenario (V, W, U, L)
8.6 Psoriasis Drugs Segment Market Forecast, 2021-2031
8.6.1 Pre-COVID Market Scenario
8.6.2 COVID-19 Impact Recovery Scenario (V, W, U, L)
8.7 Dermatitis Drugs Segment Market Forecast, 2021-2031
8.7.1 Pre-COVID Market Scenario
8.7.2 COVID-19 Impact Recovery Scenario (V, W, U, L)
8.8 Acne Drugs Segment Market Forecast, 2021-2031
8.8.1 Pre-COVID Market Scenario
8.8.2 COVID-19 Impact Recovery Scenario (V, W, U, L)
8.9 Route of Administration Segment Market Forecast, 2021-2031
8.9.1 Pre-COVID Market Scenario
8.9.2 COVID-19 Impact Recovery Scenario (V, W, U, L)
8.10 China Dermatological Drugs Market
8.10.1 Spending on healthcare for China’s vast population is on track to reach $1 trillion in 2020
8.10.2 China is now a top-three market in terms of revenue contribution, and even No. 1 for absolute revenue growth
8.10.3 Pre-COVID Market Scenario
8.10.4 COVID-19 Impact Recovery Scenario (V, W, U, L)
8.11 India Dermatological Drugs Market
8.11.1 The Indian pharmaceutical market is highly fragmented; the top 50 companies contribute 85% of the market
8.11.2 Pre-COVID Market Scenario
8.11.3 COVID-19 Impact Recovery Scenario (V, W, U, L)
8.12 Japan Dermatological Drugs Market
8.12.1 The Japanese economy is the second largest in the world
8.12.2 Pre-COVID Market Scenario
8.12.3 COVID-19 Impact Recovery Scenario (V, W, U, L)
8.13 South Korea Dermatological Drugs Market
8.13.1 Pharmaceutical spending accounted for approximately 1.7 percent of South Korea's GDP
8.13.2 The number of innovative drugs introduced in the country has also increased at a very fast pace
8.13.3 Pre-COVID Market Scenario
8.13.4 COVID-19 Impact Recovery Scenario (V, W, U, L)
8.14 Australia Dermatological Drugs Market
8.14.1 Modest growth will be driven by good market access to pharmaceutical drugs
8.14.2 The pharmaceutical market in Australia represents a knowledge-based, technology-intensive industry
8.14.3 Pre-COVID Market Scenario
8.14.4 COVID-19 Impact Recovery Scenario (V, W, U, L)
8.15 Rest of Asia Pacific Dermatological Drugs Market
8.15.1 Most of the countries in Asia Pacific adopt and implement the PIC/S GMP guide
8.15.2 Pre-COVID Market Scenario
8.15.3 COVID-19 Impact Recovery Scenario (V, W, U, L)

9 LAMEA Dermatological Drugs Market
9.1 LAMEA Market Outlook
9.1.1 Dermatological growth and development in Latin America has been significant
9.2 LAMEA Dermatological Drugs Market Estimation & Forecast
9.2.1 Pre-COVID Market Scenario
9.2.2 COVID-19 Impact Recovery Scenario (V, W, U, L)
9.3 Country Segment Dermatological Drugs Market
9.3.1 Country Share Analysis
9.3.2 Pre-COVID Market Scenario
9.3.3 COVID-19 Impact Recovery Scenario (V, W, U, L)
9.4 Disease Segment Market Forecast, 2021-2031
9.4.1 Pre-COVID Market Scenario
9.4.2 COVID-19 Impact Recovery Scenario (V, W, U, L)
9.5 Disease Segment Market Forecast, 2021-2031
9.5.1 Pre-COVID Market Scenario
9.5.2 COVID-19 Impact Recovery Scenario (V, W, U, L)
9.6 Psoriasis Drugs Segment Market Forecast, 2021-2031
9.6.1 Pre-COVID Market Scenario
9.6.2 COVID-19 Impact Recovery Scenario (V, W, U, L)
9.7 Dermatitis Drugs Segment Market Forecast, 2021-2031
9.7.1 Pre-COVID Market Scenario
9.7.2 COVID-19 Impact Recovery Scenario (V, W, U, L)
9.8 Acne Drugs Segment Market Forecast, 2021-2031
9.8.1 Pre-COVID Market Scenario
9.8.2 COVID-19 Impact Recovery Scenario (V, W, U, L)
9.9 Route of Administration Segment Market Forecast, 2021-2031
9.9.1 Pre-COVID Market Scenario
9.9.2 COVID-19 Impact Recovery Scenario (V, W, U, L)
9.10 Brazil Dermatological Drugs Market
9.10.1 The state and federal governments continue to increase spending on healthcare, the public market is becoming increasingly attractive
9.10.2 Pre-COVID Market Scenario
9.10.3 COVID-19 Impact Recovery Scenario (V, W, U, L)
9.11 Saudi Arabia Dermatological Drugs Market
9.11.1 Saudi Arabia market is witnessing increasing investment by major market players
9.11.2 Compulsory health insurance for expatriates is expected to offer lucrative growth opportunities
9.11.3 Pre-COVID Market Scenario
9.11.4 COVID-19 Impact Recovery Scenario (V, W, U, L)
9.12 South Africa Dermatological Drugs Market
9.12.1 South Africa’s pharmaceutical market is one of the most attractive markets in Africa
9.12.2 Pre-COVID Market Scenario
9.12.3 COVID-19 Impact Recovery Scenario (V, W, U, L)
9.13 Mexico Dermatological Drugs Market
9.13.1 Mexico Pharmaceutical the 11th largest pharma market in the world
9.13.2 Pre-COVID Market Scenario
9.13.3 COVID-19 Impact Recovery Scenario (V, W, U, L)
9.14 UAE Dermatological Drugs Market
9.14.1 Country Market Outlook
9.14.2 Pre-COVID Market Scenario
9.14.3 COVID-19 Impact Recovery Scenario (V, W, U, L)
9.15 Rest of LAMEA Dermatological Drugs Market
9.15.1 Pre-COVID Market Scenario
9.15.2 COVID-19 Impact Recovery Scenario (V, W, U, L)

10 Company Profiles
10.1 Abbott Laboratories Company
10.1.1 Company Information
10.1.2 Company Overview
10.1.3 Company Financial Profile
10.1.4 Company Product Offerings
10.1.5 Company Recent Developments
10.2 AbbVie Inc Company
10.2.1 Company Snapshot
10.2.2 Company Overview
10.2.3 Company Financial Profile
10.2.4 Company Product Benchmarking
10.2.5 Company Recent Developments
10.3 Bayer Pharmaceuticals Company
10.3.1 Company Snapshot
10.3.2 Company Overview
10.3.3 Company Financial Profile
10.3.4 Company Product Benchmarking
10.3.5 Company Recent Developments
10.4 Bristol-Myers Squibb Company
10.4.1 Company Snapshot
10.4.2 Company Overview
10.4.3 Company Financial Profile
10.4.4 Company Product Benchmarking
10.4.5 Company Recent Developments
10.5 Zydus Cadila Healthcare Pharmaceutical Company
10.5.1 Company Snapshot
10.5.2 Company Overview
10.5.3 Company Financial Profile
10.5.4 Company Product Benchmarking
10.5.5 Company Recent Developments
10.6 Cipla Pharmaceutical Company
10.6.1 Company Snapshot
10.6.2 Company Overview
10.6.3 Company Financial Profile
10.6.4 Company Product Benchmarking
10.6.5 Company Recent Developments
10.7 Dr. Reddy’s Laboratories Company
10.7.1 Company Snapshot
10.7.2 Company Overview
10.7.3 Company Financial Profile
10.7.4 Company Product Benchmarking
10.7.5 Company Recent Developments
10.8 Eli Lilly and Company
10.8.1 Company Snapshot
10.8.2 Company Overview
10.8.3 Company Financial Profile
10.8.4 Company Product Benchmarking
10.8.5 Company Recent Developments
10.9 GlaxoSmithKline Company
10.9.1 Company Snapshot
10.9.2 Company Overview
10.9.3 Company Financial Profile
10.9.4 Company Product Benchmarking
10.9.5 Company Recent Developments
10.10 Glenmark Pharmaceuticals Limited Company
10.10.1 Company Snapshot
10.10.2 Company Overview
10.10.3 Company Financial Profile
10.10.4 Company Product Benchmarking
10.10.5 Company Recent Developments
10.11 Johnson & Johnson Inc Company
10.11.1 Company Snapshot
10.11.2 Company Overview
10.11.3 Company Financial Profile
10.11.4 Company Product Benchmarking
10.11.5 Company Recent Developments
10.12 L’Oréal Cosmetics Company
10.12.1 Company Snapshot
10.12.2 Company Overview
10.12.3 Company Financial Profile
10.12.4 Company Product Benchmarking
10.12.5 Company Recent Developments
10.13 Lupin Limited Company
10.13.1 Company Snapshot
10.13.2 Company Overview
10.13.3 Company Financial Profile
10.13.4 Company Product Benchmarking
10.13.5 Company Recent Developments
10.14 Merck Group Chemicals Company
10.14.1 Company Snapshot
10.14.2 Company Overview
10.14.3 Company Financial Profile
10.14.4 Company Product Benchmarking
10.14.5 Company Recent Developments
10.15 Pfizer Inc Company
10.15.1 Company Snapshot
10.15.2 Company Overview
10.15.3 Company Financial Profile
10.15.4 Company Product Benchmarking
10.15.5 Company Recent Developments
10.16 F. Hoffmann-La Roche Ltd Company
10.16.1 Company Snapshot
10.16.2 Company Overview
10.16.3 Company Financial Profile
10.16.4 Company Product Benchmarking
10.16.5 Company Recent Developments
10.17 Sanofi Pasteur Pharmaceutical Company
10.17.1 Company Snapshot
10.17.2 Company Overview
10.17.3 Company Financial Profile
10.17.4 Company Product Benchmarking
10.17.5 Company Recent Developments
10.18 Sun Pharmaceutical Industries Limited Company
10.18.1 Company Snapshot
10.18.2 Company Overview
10.18.3 Company Financial Profile
10.18.4 Company Product Benchmarking
10.18.5 Company Recent Developments
10.19 Takeda Pharmaceuticals Company
10.19.1 Company Snapshot
10.19.2 Company Overview
10.19.3 Company Financial Profile
10.19.4 Company Product Benchmarking
10.19.5 Company Recent Developments
10.20 Taro Pharmaceutical Industries Ltd Company
10.20.1 Company Snapshot
10.20.2 Company Overview
10.20.3 Company Financial Profile
10.20.4 Company Product Benchmarking
10.20.5 Company Recent Developments

11 Concluding Remarks from Visiongain
11.1 Recommendations for Market Players
11.1.1 Narrow-spectrum antibiotics viable treatment option for acne
11.1.2 FDA, EMA accepts marketing applications for bimekizumab in psoriasis
11.1.3 FDA accepts NDA filing for topical papulopustular rosacea treatment
11.1.4 FDA approves ustekinumab for pediatric psoriasis
11.2 APAC Market is Poise to Grow Due to the high incidence of conditions such as acne and psoriasis

List of Tables
Table 1 Global Dermatological Drugs Market Snapshot, 2021 & 2031 (US$billion, CAGR %)
Table 2 Immunotherapeutic In Skin Diseases
Table 3 Disruptions of Clinical Trials Due to COVID-19, by Therapeutic Area (Number)
Table 4 Global Dermatological Drugs Market Forecast, 2021-2031 (USD Bn, AGR (%),CAGR(%))
Table 5 Global Dermatological Drugs Market Forecast, 2021-2031 (USD Bn, AGR (%),CAGR(%)) (V-Shape Recovery)
Table 6. Global Dermatological Drugs Market Forecast, 2021-2031 (USD Bn, AGR (%),CAGR(%)) (W-Shape Recovery)
Table 7. Global Dermatological Drugs Market Forecast, 2021-2031 (USD Bn, AGR (%),CAGR(%)) (U-Shape Recovery)
Table 8. Global Dermatological Drugs Market Forecast, 2021-2031 (USD Bn, AGR (%),CAGR(%)) (L-Shape Recovery)
Table 9. Global Dermatological Drugs Market by Region, 2021-2031 (USD Bn, AGR (%), CAGR(%))
Table 10. Global Dermatological Drugs Market by Region, 2021-2031 (USD Bn, AGR (%), CAGR(%)) (V-Shape Recovery)
Table 11. Global Dermatological Drugs Market by Region, 2021-2031 (USD Bn, AGR (%), CAGR(%)) (W-Shape Recovery)
Table 12. Global Dermatological Drugs Market by Region, 2021-2031 (USD Bn, AGR (%), CAGR(%)) (U-Shape Recovery)
Table 13. Global Dermatological Drugs Market by Region, 2021-2031 (USD Bn, AGR (%), CAGR(%)) (L-Shape Recovery)
Table 14. Global Dermatological Drugs Market by Disease, 2021-2031 (USD Bn, AGR (%), CAGR(%))
Table 15. Global Dermatological Drugs Market by Disease, 2021-2031 (USD Bn, AGR (%), CAGR(%)) (V-Shape Recovery)
Table 16. Global Dermatological Drugs Market by Disease, 2021-2031 (USD Bn, AGR (%), CAGR(%)) (W-Shape Recovery)
Table 17. Global Dermatological Drugs Market by Disease, 2021-2031 (USD Bn, AGR (%), CAGR(%)) (U-Shape Recovery)
Table 18. Global Dermatological Drugs Market by Disease, 2021-2031 (USD Bn, AGR (%), CAGR(%)) (L-Shape Recovery)
Table 19. Global Antifungals For Superficial Fungal Infections
Table 20. Global Antiviral Drugs Available
Table 21. Global Potential Drug Candidates For Skin Infection Treatments
Table 22. Global Dermatological Drugs Market by Skin Infections Drugs, 2021-2031 (USD Bn, AGR (%), CAGR(%))
Table 23. Global Dermatological Drugs Market by Skin Infections Drugs, 2021-2031 (USD Bn, AGR (%), CAGR(%)) (V-Shape Recovery)
Table 24. Global Dermatological Drugs Market by Skin Infections Drugs, 2021-2031 (USD Bn, AGR (%), CAGR(%)) (W-Shape Recovery)
Table 25. Global Dermatological Drugs Market by Skin Infections Drugs, 2021-2031 (USD Bn, AGR (%), CAGR(%)) (U-Shape Recovery)
Table 26. Global Dermatological Drugs Market by Skin Infections Drugs, 2021-2031 (USD Bn, AGR (%), CAGR(%)) (L-Shape Recovery)
Table 27. Cost Of Psoriasis Therapies In A Typical Western European Country ($)
Table 28. Global Dermatological Drugs Market by Psoriasis Drugs, 2021-2031 (USD Bn, AGR (%), CAGR(%))
Table 29. Global Dermatological Drugs Market by Psoriasis Drugs, 2021-2031 (USD Bn, AGR (%), CAGR(%)) (V-Shape Recovery)
Table 30. Global Dermatological Drugs Market by Psoriasis Drugs, 2021-2031 (USD Bn, AGR (%), CAGR(%)) (W-Shape Recovery)
Table 31. Global Dermatological Drugs Market by Psoriasis Drugs, 2021-2031 (USD Bn, AGR (%), CAGR(%)) (U-Shape Recovery)
Table 32. Global Dermatological Drugs Market by Psoriasis Drugs, 2021-2031 (USD Bn, AGR (%), CAGR(%)) (L-Shape Recovery)
Table 33. Global Products Undergoing Research As Potential Treatments For Dermatitis
Table 34. Global Dermatological Drugs Market by Dermatitis Drugs, 2021-2031 (USD Bn, AGR (%), CAGR(%))
Table 35. Global Dermatological Drugs Market by Dermatitis Drugs, 2021-2031 (USD Bn, AGR (%), CAGR(%)) (V-Shape Recovery)
Table 36. Global Dermatological Drugs Market by Dermatitis Drugs, 2021-2031 (USD Bn, AGR (%), CAGR(%)) (W-Shape Recovery)
Table 37. Global Dermatological Drugs Market by Dermatitis Drugs, 2021-2031 (USD Bn, AGR (%), CAGR(%)) (U-Shape Recovery)
Table 38. Global Dermatological Drugs Market by Dermatitis Drugs, 2021-2031 (USD Bn, AGR (%), CAGR(%)) (L-Shape Recovery)
Table 39 Global Potential Products for Acne Treatment
Table 40 Global Dermatological Drugs Market by Acne Drugs, 2021-2031 (USD Bn, AGR (%), CAGR (%))
Table 41 Global Dermatological Drugs Market by Acne Drugs, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shape Recovery)
Table 42 Global Dermatological Drugs Market by Acne Drugs, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shape Recovery)
Table 43 Global Dermatological Drugs Market by Acne Drugs, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shape Recovery)
Table 44 Global Dermatological Drugs Market by Acne Drugs, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shape Recovery)
Table 45 Global Dermatological Drugs Market by Route of Administration, 2021-2031 (USD Bn, AGR (%), CAGR (%))
Table 46 Global Dermatological Drugs Market by Route of Administration, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shape Recovery)
Table 47 Global Dermatological Drugs Market by Route of Administration, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shape Recovery)
Table 48 Global Dermatological Drugs Market by Route of Administration, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shape Recovery)
Table 49 Global Dermatological Drugs Market by Route of Administration, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shape Recovery)

Table 50 North America Dermatological Drugs Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%))
Table 51 North America Dermatological Drugs Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shape Recovery)
Table 52 North America Dermatological Drugs Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shape Recovery)
Table 53 North America Dermatological Drugs Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shape Recovery)
Table 54 North America Dermatological Drugs Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shape Recovery)
Table 55 North America Dermatological Drugs Market by Disease, 2021-2031 (USD Bn, AGR (%), CAGR (%))
Table 56 North America Dermatological Drugs Market by Disease, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shape Recovery)
Table 57 North America Dermatological Drugs Market by Disease, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shape Recovery)
Table 58 North America Dermatological Drugs Market by Disease, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shape Recovery)
Table 59 North America Dermatological Drugs Market by Disease, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shape Recovery)
Table 60 North America Dermatological Drugs Market by Skin Infections Drugs, 2021-2031 (USD Bn, AGR (%), CAGR (%))
Table 61 North America Dermatological Drugs Market by Skin Infections Drugs, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shape Recovery)
Table 62 North America Dermatological Drugs Market by Skin Infections Drugs, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shape Recovery)
Table 63 North America Dermatological Drugs Market by Skin Infections Drugs, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shape Recovery)
Table 64 North America Dermatological Drugs Market by Skin Infections Drugs, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shape Recovery)
Table 65 North America Dermatological Drugs Market by Psoriasis Drugs, 2021-2031 (USD Bn, AGR (%), CAGR (%))
Table 66 North America Dermatological Drugs Market by Psoriasis Drugs, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shape Recovery)
Table 67 North America Dermatological Drugs Market by Psoriasis Drugs, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shape Recovery)
Table 68 North America Dermatological Drugs Market by Psoriasis Drugs, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shape Recovery)
Table 69 North America Dermatological Drugs Market by Psoriasis Drugs, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shape Recovery)
Table 70 North America Dermatological Drugs Market by Dermatitis Drugs, 2021-2031 (USD Bn, AGR (%), CAGR (%))
Table 71 North America Dermatological Drugs Market by Dermatitis Drugs, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shape Recovery)
Table 72 North America Dermatological Drugs Market by Dermatitis Drugs, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shape Recovery)
Table 73 North America Dermatological Drugs Market by Dermatitis Drugs, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shape Recovery)
Table 74 North America Dermatological Drugs Market by Dermatitis Drugs, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shape Recovery)
Table 75 North America Dermatological Drugs Market by Acne Drugs, 2021-2031 (USD Bn, AGR (%), CAGR (%))
Table 76 North America Dermatological Drugs Market by Acne Drugs, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shape Recovery)
Table 77 North America Dermatological Drugs Market by Acne Drugs, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shape Recovery)
Table 78 North America Dermatological Drugs Market by Acne Drugs, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shape Recovery)
Table 79 North America Dermatological Drugs Market by Acne Drugs, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shape Recovery)
Table 80 North America Dermatological Drugs Market by Route of Administration, 2021-2031 (USD Bn, AGR (%), CAGR (%))
Table 81 North America Dermatological Drugs Market by Route of Administration, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shape Recovery)
Table 82 North America Dermatological Drugs Market by Route of Administration, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shape Recovery)
Table 83 North America Dermatological Drugs Market by Route of Administration, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shape Recovery)
Table 84 North America Dermatological Drugs Market by Route of Administration, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shape Recovery)
Table 85 US Dermatological Drugs Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%))
Table 86 US Dermatological Drugs Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shape Recovery)
Table 87 US Dermatological Drugs Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shape Recovery)
Table 88 US Dermatological Drugs Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shape Recovery)
Table 89 US Dermatological Drugs Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shape Recovery)
Table 90 Canada Dermatological Drugs Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%))
Table 91 Canada Dermatological Drugs Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shape Recovery)
Table 92 Canada Dermatological Drugs Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shape Recovery)
Table 93 Canada Dermatological Drugs Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shape Recovery)
Table 94 Canada Dermatological Drugs Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shape Recovery)
Table 95 Europe Dermatological Drugs Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%))
Table 96 Europe Dermatological Drugs Market Forecast, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shape Recovery)
Table 97 Europe Dermatological Drugs Market Forecast, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shape Recovery)
Table 98 Europe Dermatological Drugs Market Forecast, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shape Recovery)
Table 99 Europe Dermatological Drugs Market Forecast, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shape Recovery)
Table 100 Europe Dermatological Drugs Market by Disease, 2021-2031 (USD Bn, AGR (%), CAGR (%))
Table 101 Europe Dermatological Drugs Market by Disease, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shape Recovery)
Table 102 Europe Dermatological Drugs Market by Disease, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shape Recovery)
Table 103 Europe Dermatological Drugs Market by Disease, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shape Recovery)
Table 104 Europe Dermatological Drugs Market by Disease, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shape Recovery)
Table 105 Europe Dermatological Drugs Market by Skin Infections Drugs, 2021-2031 (USD Bn, AGR (%), CAGR (%))
Table 106 Europe Dermatological Drugs Market by Skin Infections Drugs, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shape Recovery)
Table 107 Europe Dermatological Drugs Market by Skin Infections Drugs, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shape Recovery)
Table 108 Europe Dermatological Drugs Market by Skin Infections Drugs, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shape Recovery)
Table 109 Europe Dermatological Drugs Market by Skin Infections Drugs, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shape Recovery)
Table 110 Europe Dermatological Drugs Market by Psoriasis Drugs, 2021-2031 (USD Bn, AGR (%), CAGR (%))
Table 111 Europe Dermatological Drugs Market by Psoriasis Drugs, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shape Recovery)
Table 112 Europe Dermatological Drugs Market by Psoriasis Drugs, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shape Recovery)
Table 113 Europe Dermatological Drugs Market by Psoriasis Drugs, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shape Recovery)
Table 114 Europe Dermatological Drugs Market by Psoriasis Drugs, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shape Recovery)
Table 115 Europe Dermatological Drugs Market by Dermatitis Drugs, 2021-2031 (USD Bn, AGR (%), CAGR (%))
Table 116 Europe Dermatological Drugs Market by Dermatitis Drugs, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shape Recovery)
Table 117 Europe Dermatological Drugs Market by Dermatitis Drugs, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shape Recovery)
Table 118 Europe Dermatological Drugs Market by Dermatitis Drugs, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shape Recovery)
Table 119 Europe Dermatological Drugs Market by Dermatitis Drugs, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shape Recovery)
Table 120 Europe Dermatological Drugs Market by Acne Drugs, 2021-2031 (USD Bn, AGR (%), CAGR (%))
Table 121 Europe Dermatological Drugs Market by Acne Drugs, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shape Recovery)
Table 122 Europe Dermatological Drugs Market by Acne Drugs, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shape Recovery)
Table 123 Europe Dermatological Drugs Market by Acne Drugs, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shape Recovery)
Table 124 Europe Dermatological Drugs Market by Acne Drugs, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shape Recovery)
Table 125 Europe Dermatological Drugs Market by Route of Administration, 2021-2031 (USD Bn, AGR (%), CAGR (%))
Table 126 Europe Dermatological Drugs Market by Route of Administration, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shape Recovery)
Table 127 Europe Dermatological Drugs Market by Route of Administration, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shape Recovery)
Table 128 Europe Dermatological Drugs Market by Route of Administration, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shape Recovery)
Table 129 Europe Dermatological Drugs Market by Route of Administration, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shape Recovery)
Table 130 Germany Dermatological Drugs Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%))
Table 131 Germany Dermatological Drugs Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shape Recovery)
Table 132 Germany Dermatological Drugs Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shape Recovery)
Table 133 Germany Dermatological Drugs Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shape Recovery)
Table 134 Germany Dermatological Drugs Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shape Recovery)
Table 135 UK Dermatological Drugs Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%))
Table 136 UK Dermatological Drugs Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shape Recovery)
Table 137 UK Dermatological Drugs Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shape Recovery)
Table 138 UK Dermatological Drugs Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shape Recovery)
Table 139 UK Dermatological Drugs Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shape Recovery)
Table 140 France Dermatological Drugs Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%))
Table 141 France Dermatological Drugs Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shape Recovery)
Table 142 France Dermatological Drugs Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shape Recovery)
Table 143 France Dermatological Drugs Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shape Recovery)
Table 144 France Dermatological Drugs Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shape Recovery)
Table 145 Italy Dermatological Drugs Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%))
Table 146 Italy Dermatological Drugs Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shape Recovery)
Table 147 Italy Dermatological Drugs Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shape Recovery)
Table 148 Italy Dermatological Drugs Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shape Recovery)
Table 149 Italy Dermatological Drugs Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shape Recovery)
Table 150 Spain Dermatological Drugs Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%))
Table 151 Spain Dermatological Drugs Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shape Recovery)
Table 152 Spain Dermatological Drugs Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shape Recovery)
Table 153 Spain Dermatological Drugs Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shape Recovery)
Table 154 Spain Dermatological Drugs Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shape Recovery)
Table 155 Rest of Europe Dermatological Drugs Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%))
Table 156 Rest of Europe Dermatological Drugs Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shape Recovery)
Table 157 Rest of Europe Dermatological Drugs Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shape Recovery)
Table 158 Rest of Europe Dermatological Drugs Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shape Recovery)
Table 159 Rest of Europe Dermatological Drugs Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shape Recovery)
Table 160 Asia-Pacific Dermatological Drugs Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR(%))
Table 161 Asia Pacific Dermatological Drugs Market Forecast, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shape Recovery)
Table 162 Asia Pacific Dermatological Drugs Market Forecast, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shape Recovery)
Table 163 Asia Pacific Dermatological Drugs Market Forecast, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shape Recovery)
Table 164 Asia Pacific Dermatological Drugs Market Forecast, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shape Recovery)
Table 165 Asia-Pacific Dermatological Drugs Market by Disease, 2021-2031 (USD Bn, AGR (%), CAGR (%))
Table 166 Asia Pacific Dermatological Drugs Market by Disease, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shape Recovery)
Table 167 Asia Pacific Dermatological Drugs Market by Disease, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shape Recovery)
Table 168 Asia Pacific Dermatological Drugs Market by Disease, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shape Recovery)
Table 169 Asia Pacific Dermatological Drugs Market by Disease, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shape Recovery)
Table 170 Asia-Pacific Dermatological Drugs Market by Skin Infections Drugs, 2021-2031 (USD Bn, AGR (%), CAGR (%))
Table 171 Asia Pacific Dermatological Drugs Market by Skin Infections Drugs, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shape Recovery)
Table 172 Asia Pacific Dermatological Drugs Market by Skin Infections Drugs, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shape Recovery)
Table 173 Asia Pacific Dermatological Drugs Market by Skin Infections Drugs, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shape Recovery)
Table 174 Asia Pacific Dermatological Drugs Market by Skin Infections Drugs, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shape Recovery)
Table 175 Asia-Pacific Dermatological Drugs Market by Psoriasis Drugs, 2021-2031 (USD Bn, AGR (%), CAGR (%))
Table 176 Asia Pacific Dermatological Drugs Market by Psoriasis Drugs, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shape Recovery)
Table 177 Asia Pacific Dermatological Drugs Market by Psoriasis Drugs, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shape Recovery)
Table 178 Asia Pacific Dermatological Drugs Market by Psoriasis Drugs, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shape Recovery)
Table 179 Asia Pacific Dermatological Drugs Market by Psoriasis Drugs, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shape Recovery)
Table 180 Asia-Pacific Dermatological Drugs Market by Dermatitis Drugs, 2021-2031 (USD Bn, AGR (%), CAGR (%))
Table 181 Asia Pacific Dermatological Drugs Market by Dermatitis Drugs, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shape Recovery)
Table 182 Asia Pacific Dermatological Drugs Market by Dermatitis Drugs, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shape Recovery)
Table 183 Asia Pacific Dermatological Drugs Market by Dermatitis Drugs, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shape Recovery)
Table 184 Asia Pacific Dermatological Drugs Market by Dermatitis Drugs, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shape Recovery)
Table 185 Asia-Pacific Dermatological Drugs Market by Acne Drugs, 2021-2031 (USD Bn, AGR (%), CAGR (%))
Table 186 Asia Pacific Dermatological Drugs Market by Acne Drugs, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shape Recovery)
Table 187 Asia Pacific Dermatological Drugs Market by Acne Drugs, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shape Recovery)
Table 188 Asia Pacific Dermatological Drugs Market by Acne Drugs, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shape Recovery)
Table 189 Asia Pacific Dermatological Drugs Market by Acne Drugs, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shape Recovery)
Table 190 Asia Pacific Dermatological Drugs Market by Route of Administration, 2021-2031 (USD Bn, AGR (%), CAGR (%))
Table 191 Asia Pacific Dermatological Drugs Market by Route of Administration, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shape Recovery)
Table 192 Asia Pacific Dermatological Drugs Market by Route of Administration, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shape Recovery)
Table 193 Asia Pacific Dermatological Drugs Market by Route of Administration, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shape Recovery)
Table 194 Asia Pacific Dermatological Drugs Market by Route of Administration, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shape Recovery)
Table 195 China Dermatological Drugs Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%))
Table 196 China Dermatological Drugs Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shape Recovery)
Table 197 China Dermatological Drugs Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shape Recovery)
Table 198 China Dermatological Drugs Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shape Recovery)
Table 199 China Dermatological Drugs Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shape Recovery)
Table 200 India Dermatological Drugs Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%))
Table 201 India Dermatological Drugs Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shape Recovery)
Table 202 India Dermatological Drugs Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shape Recovery)
Table 203 India Dermatological Drugs Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shape Recovery)
Table 204 India Dermatological Drugs Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shape Recovery)
Table 205 Japan Dermatological Drugs Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%))
Table 206 Japan Dermatological Drugs Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shape Recovery)
Table 207 Japan Dermatological Drugs Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shape Recovery)
Table 208 Japan Dermatological Drugs Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shape Recovery)
Table 209 Japan Dermatological Drugs Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shape Recovery)
Table 210 South Korea Dermatological Drugs Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%))
Table 211 South Korea Dermatological Drugs Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shape Recovery)
Table 212 South Korea Dermatological Drugs Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shape Recovery)
Table 213 South Korea Dermatological Drugs Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shape Recovery)
Table 214 South Korea Dermatological Drugs Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shape Recovery)
Table 215 Australia Dermatological Drugs Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%))
Table 216 Australia Dermatological Drugs Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shape Recovery)
Table 217 Australia Dermatological Drugs Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shape Recovery)
Table 218 Australia Dermatological Drugs Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shape Recovery)
Table 219 Australia Dermatological Drugs Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shape Recovery)
Table 220 Rest of Asia-Pacific Dermatological Drugs Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%))
Table 221 Rest of Asia-Pacific Dermatological Drugs Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shape Recovery)
Table 222 Rest of Asia-Pacific Dermatological Drugs Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shape Recovery)
Table 223 Rest of Asia-Pacific Dermatological Drugs Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shape Recovery)
Table 224 Rest of Asia-Pacific Dermatological Drugs Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shape Recovery)
Table 225 LAMEA Dermatological Drugs Market by Value, 2021-2031 (USD Bn, AGR (%), CAGR (%))
Table 226 LAMEA Dermatological Drugs Market Forecast, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shape Recovery)
Table 227 LAMEA Dermatological Drugs Market Forecast, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shape Recovery)
Table 228 LAMEA Dermatological Drugs Market Forecast, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shape Recovery)
Table 229 LAMEA Dermatological Drugs Market Forecast, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shape Recovery)
Table 230 LAMEA Dermatological Drugs Market by Disease, 2021-2031 (USD Bn, AGR (%), CAGR (%))
Table 231 LAMEA Dermatological Drugs Market by Disease, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shape Recovery)
Table 232 LAMEA Dermatological Drugs Market by Disease, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shape Recovery)
Table 233 LAMEA Dermatological Drugs Market by Disease, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shape Recovery)
Table 234 LAMEA Dermatological Drugs Market by Disease, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shape Recovery)
Table 235 LAMEA Dermatological Drugs Market by Skin Infections Drugs, 2021-2031 (USD Bn, AGR (%), CAGR (%))
Table 236 LAMEA Dermatological Drugs Market by Skin Infections Drugs, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shape Recovery)
Table 237 LAMEA Dermatological Drugs Market by Skin Infections Drugs, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shape Recovery)
Table 238 LAMEA Dermatological Drugs Market by Skin Infections Drugs, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shape Recovery)
Table 239 LAMEA Dermatological Drugs Market by Skin Infections Drugs, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shape Recovery)
Table 240 LAMEA Dermatological Drugs Market by Psoriasis Drugs, 2021-2031 (USD Bn, AGR (%), CAGR (%))
Table 241 LAMEA Dermatological Drugs Market by Psoriasis Drugs, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shape Recovery)
Table 242 LAMEA Dermatological Drugs Market by Psoriasis Drugs, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shape Recovery)
Table 243 LAMEA Dermatological Drugs Market by Psoriasis Drugs, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shape Recovery)
Table 244 LAMEA Dermatological Drugs Market by Psoriasis Drugs, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shape Recovery)
Table 245 LAMEA Dermatological Drugs Market by Dermatitis Drugs, 2021-2031 (USD Bn, AGR (%), CAGR (%))
Table 246 LAMEA Dermatological Drugs Market by Dermatitis Drugs, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shape Recovery)
Table 247 LAMEA Dermatological Drugs Market by Dermatitis Drugs, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shape Recovery)
Table 248 LAMEA Dermatological Drugs Market by Dermatitis Drugs, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shape Recovery)
Table 249 LAMEA Dermatological Drugs Market by Dermatitis Drugs, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shape Recovery)
Table 250 LAMEA Dermatological Drugs Market by Acne Drugs, 2021-2031 (USD Bn, AGR (%), CAGR (%))
Table 251 LAMEA Dermatological Drugs Market by Acne Drugs, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shape Recovery)
Table 252 LAMEA Dermatological Drugs Market by Acne Drugs, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shape Recovery)
Table 253 LAMEA Dermatological Drugs Market by Acne Drugs, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shape Recovery)
Table 254 LAMEA Dermatological Drugs Market by Acne Drugs, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shape Recovery)
Table 255 LAMEA Dermatological Drugs Market by Route of Administration, 2021-2031 (USD Bn, AGR (%), CAGR (%))
Table 256 LAMEA Dermatological Drugs Market by Route of Administration, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shape Recovery)
Table 257 LAMEA Dermatological Drugs Market by Route of Administration, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shape Recovery)
Table 258 LAMEA Dermatological Drugs Market by Route of Administration, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shape Recovery)
Table 259 LAMEA Dermatological Drugs Market by Route of Administration, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shape Recovery)
Table 260 Brazil Dermatological Drugs Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%))
Table 261 Brazil Dermatological Drugs Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shape Recovery)
Table 262 Brazil Dermatological Drugs Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shape Recovery)
Table 263 Brazil Dermatological Drugs Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shape Recovery)
Table 264 Brazil Dermatological Drugs Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shape Recovery)
Table 265 Saudi Arabia Dermatological Drugs Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%))
Table 266 Saudi Arabia Dermatological Drugs Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shape Recovery)
Table 267 Saudi Arabia Dermatological Drugs Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shape Recovery)
Table 268 Saudi Arabia Dermatological Drugs Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shape Recovery)
Table 269 Saudi Arabia Dermatological Drugs Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shape Recovery)
Table 270 South Africa Dermatological Drugs Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%))
Table 271 South Africa Dermatological Drugs Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shape Recovery)
Table 272 South Africa Dermatological Drugs Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shape Recovery)
Table 273 South Africa Dermatological Drugs Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shape Recovery)
Table 274 South Africa Dermatological Drugs Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shape Recovery)
Table 275 Mexico Dermatological Drugs Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%))
Table 276 Mexico Dermatological Drugs Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shape Recovery)
Table 277 Mexico Dermatological Drugs Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shape Recovery)
Table 278 Mexico Dermatological Drugs Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shape Recovery)
Table 279 Mexico Dermatological Drugs Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shape Recovery)
Table 280 UAE Dermatological Drugs Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%))
Table 281 UAE Dermatological Drugs Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shape Recovery)
Table 282 UAE Dermatological Drugs Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shape Recovery)
Table 283 UAE Dermatological Drugs Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shape Recovery)
Table 284 UAE Dermatological Drugs Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shape Recovery)
Table 285 Rest of LAMEA Dermatological Drugs Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%))
Table 286 Rest of LAMEA Dermatological Drugs Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (V-Shape Recovery)
Table 287 Rest of LAMEA Dermatological Drugs Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (W-Shape Recovery)
Table 288 Rest of LAMEA Dermatological Drugs Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (U-Shape Recovery)
Table 289 Rest of LAMEA Dermatological Drugs Market by Country, 2021-2031 (USD Bn, AGR (%), CAGR (%)) (L-Shape Recovery)
Table 290. Abbott Laboratories: Company Information
Table 291. Abbott Laboratories: Company Revenue 2015-2019 (US$ Million, AGR %)
Table 292. Abbott Laboratories: Company Product and Service Offerings
Table 293. Abbott Laboratories: Company Product Pipeline
Table 294. Abbott Laboratories: Company Recent Developments till Sept,2020
Table 295. AbbVie Inc: Company Information
Table 296. AbbVie Inc: Company Revenue 2015-2019 (US$ Million, AGR %)
Table 297. AbbVie Inc: Company Product and Service Benchmarking
Table 298. AbbVie Inc: Company Product Pipeline
Table 299. AbbVie Inc: Company Recent Developments till December,2020
Table 300. Bayer Pharmaceuticals: Company Information
Table 301. Bayer Pharmaceuticals: Company Revenue 2015-2019 (US$ Million, AGR %)
Table 302. Bayer Pharmaceuticals: Company Product and Service Benchmarking
Table 303. Bayer Pharmaceuticals: Company Product Pipeline
Table 304. Bayer Pharmaceuticals: Company Recent Developments till December,2020
Table 305. Bristol-Myers Squibb: Company Information
Table 306. Bristol-Myers Squibb: Company Revenue 2015-2019 (US$ Million, AGR %)
Table 307. Bristol-Myers Squibb: Company Product and Service Benchmarking
Table 308. Bristol-Myers Squibb: Company Product Pipeline
Table 309. Bristol-Myers Squibb: Company Recent Developments till December,2020
Table 310. Zydus Cadila Healthcare Pharmaceuticals: Company Information
Table 311. Zydus Cadila Healthcare Pharmaceuticals: Company Revenue 2015-2019 (US$ Million, AGR %)
Table 312. Zydus Cadila Healthcare Pharmaceuticals: Company Product and Service Benchmarking
Table 313. Zydus Cadila Healthcare Pharmaceuticals: Company Recent Developments till December,2020
Table 314. Cipla Pharmaceutical: Company Information
Table 315. Cipla Pharmaceutical: Company Revenue 2015-2019 (US$ Million, AGR %)
Table 316. Cipla Pharmaceutical: Company Product and Service Benchmarking
Table 317. Cipla Pharmaceutical: Company Product Pipeline
Table 318. Cipla Pharmaceutical: Company Recent Developments till December,2020
Table 319. Dr. Reddy’s Laboratories: Company Information
Table 320. Dr. Reddy’s Laboratories: Company Revenue 2015-2019 (US$ Million, AGR %)
Table 321. Dr. Reddy’s Laboratories: Company Product and Service Benchmarking
Table 322. Dr. Reddy’s Laboratories: Company Product Pipeline
Table 323. Dr. Reddy’s Laboratories: Company Recent Developments till December,2020
Table 324. Eli Lilly and Company: Company Information
Table 325. Eli Lilly and Company: Company Revenue 2015-2019 (US$ Million, AGR %)
Table 326. Eli Lilly and Company: Company Product and Service Benchmarking
Table 327. Eli Lilly and Company: Company Product Pipeline
Table 328. Eli Lilly and Company: Company Recent Developments till December,2020
Table 329. GlaxoSmithKline: Company Information
Table 330. GlaxoSmithKline: Company Revenue 2015-2019 (US$ Million, AGR %)
Table 331. GlaxoSmithKline: Company Product and Service Benchmarking
Table 332. GlaxoSmithKline: Company Product Pipeline
Table 333. GlaxoSmithKline: Company Recent Developments till December,2020
Table 334. Glenmark Pharmaceuticals Limited: Company Information
Table 335. Glenmark

この商品のレポートナンバー

0000028695

TOP